Protective effect of CCR2-64I and not of CCR5-Δ32 and SDF1-3'A in pediatric HIV-1 infection

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 23, Issue 1, 2000, Pages 52-57

  Mangano, A ^a   Kopka, J ^a   Batalla, M ^a   Bologna, R ^a   Sen, Luisa ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

CCR2; CCR5; Chemokine receptors; HIV 1; Pediatric AIDS; SDF1; Vertical transmission

Indexed keywords

CHEMOKINE RECEPTOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ARTICLE; CHILD; CHILDHOOD DISEASE; DISEASE COURSE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PERINATAL INFECTION; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034051733     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200001010-00007     Document Type: Article

References (40)

1. Feng Y, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-7.
2. Berson JF, et al. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996;70:6288-95.
3. Deng HK, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996;381:661-6.
4. + cells is mediated by the chemokine receptor CC-CKR5. Nature 1996;381:667-73.
5. Choe H, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48.
6. Doranz BJ, et al. A dual-tropic, primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 1996;85:1149-59.
7. Dean M, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62.
8. Michael NL, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40.
9. Smith MW, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997;277:959-65.
10. Michael NL, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997;3: 1160-2.
11. Liu R, et al. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
12. Samson M, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.
13. Biti R, et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997;3:252-3.
14. Ballota C, et al. Homozygous Δ32 deletion of the CCR5 chemokine receptor gene in an HIV-1 infected patient. AIDS 1997;11: F67-71.
15. O'Brien T, et al. HIV-1 infection in a man homozygous for CCR5 Δ32. Lancet 1997;349:1219.
16. Theodorou I, et al. and the Seroco Study Group. HIV-1 infection in an individual homozygous for CCR5 Δ32. Lancet 1997;349:1219-20.
17. Heiken H, et al. HIV-1 infection in a heterosexual man homozygous for CCR5 delta 32. AIDS 1999;13:529-30.
18. Kuipers H, et al. An HIV-1 infected individual homozygous for the CCR5 delta 32 allele and the SDF-1 3′A allele. AIDS 1999;13: 433-4.
19. Connor RI, et al. Change in coreceptor use correlates with disease progression in HIV-infected individuals. J Exp Med 1997;185: 621-8.
20. Xiao L, et al. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998;12:F137-43.
21. Meyer L, et al. Early protective effect of CCR5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS 1997;11:F73-8.
22. Katzenstein TL, et al. HIV-infected individuals with the CCR5-Δ32/CCR5 genotype have lower HIV-RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:10-14.
23. Eugen-Olsen J, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11:305-10.
24. Ioannidis JPA, et al. Genetic effects on HIV disease progression. Nat Med 1998;4:536.
25. Mummidi S, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998;4:786-93.
26. Kostrikis LG, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998;4:350-3.
27. Winkler C, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998;279:389-93.
28. Eskild A, et al. The estimated impact of the CCR-5 Δ32 gene deletion on HIV disease progression varies with study design. AIDS 1998;12:2271-4.
29. Mangano A, et al. Distribution of CCR-5 Δ32 allele in Argentinian children at risk of HIV-1 infection: its role in vertical transmission. AIDS 1998;12:109-10.
30. Misrahi M, et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. JAMA 1998;279:277-80.
31. Esposito S, et al. Role of CCR5 chemokine receptor gene in vertical human immunodeficiency virus type 1 transmission and disease progression. Pediatr Infect Dis J 1998;17:847-9.
32. Rousseau CM, et al. CCR5del32 in perinatal HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:239-42.
33. Eldestein R, et al. Risk of mother-to-infant transmission of HIV-1 is not reduced in CCR5/Δ32ccr5 heterozygotes. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:243-4.
34. U.S. Centers for Disease Control and Prevention. Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep 1994; 43:1-10.
35. Connor EM, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
36. Pizzo PA, et al. Treatment considerations for children with HIV infection. In: Pediatric AIDS. The challenge of HIV infection in infants, children and adolescents. Baltimore: Williams & Wilkins, 1991:478:494.
37. U.S. Department of Health and Human Services. Antiretroviral agents in pediatric HIV infection. MMWR Morbid Mortal Weekly Rep 1998;47:1-44.
38. Martinson JJ, et al. Global distribution of the CCR5 gene 32-base pair deletion. Nat Gen 1997;16:100-3.
39. Mariani R, et al. CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol 1999;73: 2450-9.
40. van Rij RP, et al. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998;12:F85-90.